Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465748 | 1.00 | HTR3E (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL17196033 | 0.85 | TTR (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL177526 | 0.84 | TTR (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL257875 | 0.81 | CA1 (0.47) | KDRMGLLIDO1 | |
| SCHEMBL3789433 | 0.81 | MGLL (0.52) | MGLLTTRENPP2 | |
| SCHEMBL29700447 | 0.81 | MGLL (0.52) | MGLLTTRENPP2 | |
| SCHEMBL29525231 | 0.78 | MGLL (0.48) | MGLLENPP2 | |
| SCHEMBL7895094 | 0.78 | MGLL (0.48) | MGLLTTRENPP2LMNA | |
| SCHEMBL206793 | 0.78 | MGLL (0.48) | MGLLENPP2 | |
| SCHEMBL23229016 | 0.77 | IDO1 (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874534-A | Carboxamide group-based ionic iridium (III) complex, preparation method thereof and application thereof in fluoride ion detection | 桂林理工大学 | 2023-10-13 | — | — | CN | claimed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | claimed |
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | claimed |
| EP-2948451-B1 | SUBSTITUTED PURINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-07-12 | — | — | EP | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| EP-1928875-B1 | 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | claimed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260035360-A1 | INHIBITORS OF MYC AND USES THEREOF | UNIV NORTHWESTERN (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-4561568-A2 | INHIBITORS OF MYC AND USES THEREOF | Northwestern University (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-116472266-B | Compounds as prolyl hydroxylase inhibitors and methods of making the same | 苏中药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025076088-A1 | LACTAMS FOR USE AS SARM1 INHIBITORS | GENENTECH, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996009046-A1 | 5α-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0703221-A1 | 5 alpha-reductase Inhibitors | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | BCL2L11, BCL2, BCL2L2 | HTR3E 4313/4885HTR3B 3917/4885HTR3A 4519/4885 |
| US-20260035360-A1 | INHIBITORS OF MYC AND USES THEREOF | MYC, MYCBP, MYCBP2 | HTR3E 2506/4885HTR3B 3311/4885HTR3A 3130/4885 |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2, BAX, BCL2L2 | HTR3E 3932/4885HTR3B 3635/4885HTR3A 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.